PremiumCompany AnnouncementsAura Biosciences Advances in Cancer Therapy Trials Aura Biosciences Raises $69.9 Million in Public Offering Aura Biosciences: Strategic Advancements and Clinical Progress Drive Buy Rating PremiumCompany AnnouncementsAura Biosciences Expands Board with New Director Appointment Aura Biosciences appoints Bitetti to board of directors Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating PremiumRatingsPromising Clinical Data and Abscopal Effect Drive Buy Rating for Aura Biosciences Inc. Promising Phase 1 Results for Aura Biosciences’ Bel-sar in Bladder Cancer Boost Buy Rating Buy Recommendation for Aura Biosciences: Promising Phase 1 Trial Results and Dual Mechanism of Action in Bladder Cancer Treatment